LB Pharmaceuticals Inc Common Stock
LBRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.37B
Close$
$9.75
80.3% downside
Current Fair Value
80.3% downsideOvervalued by 80.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.37 Billion |
|---|---|
| Enterprise Value | $1.09 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1 |
| Beta | 0.42 |
| Outstanding Shares | 30,137,000 |
Return
| Return on Equity | -25.78% |
|---|---|
| Return on Assets | -23.69% |
| Return on Invested Capital | -27.64% |
Valuation & Multiples
| P/E Ratio | -16.07 |
|---|---|
| PEG | -6.09 |
| Price to Sales | - |
| Price to Book Ratio | 4.5 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -11.67 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.80
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-1.61
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 107.89%▼ 3.62% |
|---|---|
| Total Invested | $988.06M▲ 42.70% |
| Investors Holding | 117▲ 40.00% |
ESG Score
No data
About LB Pharmaceuticals Inc Common Stock
16 employees
CEO: Heather D. Turner Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.